[go: up one dir, main page]

SG10201913262RA - Factor xi antibodies and methods of use - Google Patents

Factor xi antibodies and methods of use

Info

Publication number
SG10201913262RA
SG10201913262RA SG10201913262RA SG10201913262RA SG10201913262RA SG 10201913262R A SG10201913262R A SG 10201913262RA SG 10201913262R A SG10201913262R A SG 10201913262RA SG 10201913262R A SG10201913262R A SG 10201913262RA SG 10201913262R A SG10201913262R A SG 10201913262RA
Authority
SG
Singapore
Prior art keywords
antibodies
factor
methods
Prior art date
Application number
SG10201913262RA
Other languages
English (en)
Inventor
Jorg Eder
Stefan Ewert
Ulrich Hassiepen
Yasser Khder
Lorenz M Mayr
Samu Melkko
Nikolaus Schiering
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG10201913262RA publication Critical patent/SG10201913262RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201913262RA 2015-06-26 2016-06-24 Factor xi antibodies and methods of use SG10201913262RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562184955P 2015-06-26 2015-06-26
US201662341568P 2016-05-25 2016-05-25

Publications (1)

Publication Number Publication Date
SG10201913262RA true SG10201913262RA (en) 2020-03-30

Family

ID=56296875

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201913262RA SG10201913262RA (en) 2015-06-26 2016-06-24 Factor xi antibodies and methods of use

Country Status (28)

Country Link
US (4) US20180355056A1 (ru)
EP (1) EP3313891A1 (ru)
JP (4) JP6698711B2 (ru)
KR (2) KR102059059B1 (ru)
CN (3) CN114380914A (ru)
AU (4) AU2016281957B2 (ru)
CA (1) CA2990764A1 (ru)
CL (1) CL2017003261A1 (ru)
CO (1) CO2017013356A2 (ru)
CR (1) CR20170600A (ru)
CU (1) CU24498B1 (ru)
EA (1) EA036395B1 (ru)
EC (1) ECSP18005520A (ru)
HK (1) HK1250990A1 (ru)
IL (3) IL295859B2 (ru)
JO (2) JOP20200312A1 (ru)
MA (1) MA42243A (ru)
MX (2) MX391310B (ru)
MY (2) MY194928A (ru)
PE (1) PE20180480A1 (ru)
PH (2) PH12021551700A1 (ru)
RU (1) RU2739946C2 (ru)
SG (1) SG10201913262RA (ru)
TN (1) TN2017000536A1 (ru)
TW (2) TWI820482B (ru)
UY (1) UY36751A (ru)
WO (1) WO2016207858A1 (ru)
ZA (1) ZA201708589B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297207B1 (en) * 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
MX378572B (es) 2016-01-22 2025-03-11 Merck Sharp & Dohme Llc Anticuerpos anti-factor de la coagulacion xi.
AU2017236063B2 (en) * 2016-03-23 2024-06-13 Prothix Bv Monoclonal antibodies against the active site of factor XI and uses thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI802193B (zh) 2016-06-14 2023-05-11 美商默沙東有限責任公司 抗凝血因子ｘｉ抗體
AU2017329645A1 (en) 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
CN110325550B (zh) * 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
AU2017383537B2 (en) * 2016-12-23 2024-10-03 Novartis Ag Methods of treatment with anti-Factor XI/XIa antibodies
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
CN111902427A (zh) * 2017-11-22 2020-11-06 诺华股份有限公司 抗因子XI/XIa抗体的逆转结合剂及其用途
GB2569144B (en) * 2017-12-06 2021-06-16 Proimmune Ltd Method for screening the activity of mutated expressed polypeptides
CN108220274B (zh) 2017-12-11 2021-02-26 上海交通大学医学院附属瑞金医院 一种高活性凝血因子xi突变体及其基因治疗/编辑载体、重组/融合蛋白的制备与应用
MX2021001613A (es) * 2018-08-09 2021-04-28 Shanghai Benemae Pharmaceutical Corp Anticuerpos anti-factor xi.
US12258419B2 (en) * 2019-04-16 2025-03-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-FXI/FXIa antibody and use thereof
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
WO2021127525A1 (en) * 2019-12-20 2021-06-24 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
JP7807081B2 (ja) * 2020-07-02 2026-01-27 北京拓界生物医薬科技有限公司 抗ＦＸＩ／ＦＸＩａ抗体、その抗原結合断片と医薬用途
AU2021401421A1 (en) * 2020-12-18 2023-06-22 Anthos Therapeutics, Inc. Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies
WO2023092062A1 (en) * 2021-11-18 2023-05-25 Anthos Therapeutics, Inc. Dosing regimens of factor xi/xia antibodies
KR20250103634A (ko) 2022-11-07 2025-07-07 리제너론 파아마슈티컬스, 인크. 인자 xi 촉매 도메인 결합 항체 및 이의 사용 방법
EP4662230A1 (en) 2023-02-08 2025-12-17 ImmunOs Therapeutics AG Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPH0656382B2 (ja) 1985-09-17 1994-07-27 和光純薬工業株式会社 活性型ヒト血液凝固第▲ｘｉ▼因子の免疫学的定量法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0517895T3 (da) 1990-12-14 1997-04-07 Univ California Kimæriske kæder til receptorforbundne signaltransduktionsveje
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
AU1397895A (en) 1993-12-22 1995-07-10 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the activated platelet binding site on factor xi
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
FR2718312B1 (fr) 1994-03-29 1996-06-07 Rola Nevoux Procédé d'authentification combinée d'un terminal de télécommunication et d'un module d'utilisateur.
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
CA2304254C (en) 1997-06-11 2012-05-22 Hans Christian Thogersen Trimerising module
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
DK1176195T3 (da) 1999-04-09 2013-06-24 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE60041119D1 (de) 1999-07-20 2009-01-29 Morphosys Ag Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2437814C (en) 2001-02-12 2008-05-13 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89)
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
JP4298498B2 (ja) 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
RS51829B (sr) 2001-08-23 2012-02-29 Genmab A/S. Ljudska antitela specifična za interleukin 15 (il-15)
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7217794B2 (en) 2003-04-02 2007-05-15 Daiamed, Inc. Compounds and methods for treatment of thrombosis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
CA2529001A1 (en) 2003-06-10 2004-12-16 Catchmabs B.V. Binding peptides: methods for their generation and use
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1773771A2 (en) 2004-07-23 2007-04-18 Daiamed, Inc. Compounds and methods for treatment of thrombosis
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
CA2648522A1 (en) 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
ATE511502T1 (de) 2005-12-14 2011-06-15 Bristol Myers Squibb Co Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
WO2009067660A2 (en) 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
JP5537442B2 (ja) 2008-03-13 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー 第ｘｉａ因子阻害剤としてのピリダジン誘導体
FR2931481B1 (fr) 2008-05-23 2013-05-10 Covalab Anticorps specifique de la lysine propionylee/butyrylee, son procede d'obtention et ses applications
EP2297207B1 (en) 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
RU2535964C2 (ru) 2008-10-15 2014-12-20 АйЭсАйЭс ФАРМАСЬЮТИКАЛЗ, ИНК. Модуляция экспрессии фактора 11
LT2373691T (lt) 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
US8940833B2 (en) 2013-03-15 2015-01-27 Brady Worldwide, Inc. Polyester-based, pressure sensitive adhesive
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
RU2018103173A (ru) 2015-08-06 2019-09-06 Гликотоп Гмбх Гетеромеры, содержащие слитые белки доменов антител
MX378572B (es) 2016-01-22 2025-03-11 Merck Sharp & Dohme Llc Anticuerpos anti-factor de la coagulacion xi.
AU2017236063B2 (en) 2016-03-23 2024-06-13 Prothix Bv Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI802193B (zh) 2016-06-14 2023-05-11 美商默沙東有限責任公司 抗凝血因子ｘｉ抗體
AU2017329645A1 (en) 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
KR20190052027A (ko) 2016-09-23 2019-05-15 씨에스엘 리미티드 응고 인자 결합 단백질 및 이의 용도
AU2017383537B2 (en) 2016-12-23 2024-10-03 Novartis Ag Methods of treatment with anti-Factor XI/XIa antibodies
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
PE20191476A1 (es) 2017-01-19 2019-10-16 Bayer Pharma AG Nueva formulacion estable de anticuerpos anti-fxia

Also Published As

Publication number Publication date
NZ738480A (en) 2025-03-28
PH12021551700A1 (en) 2022-11-07
AU2016281957A1 (en) 2018-01-18
IL295859B1 (en) 2025-03-01
RU2739946C2 (ru) 2020-12-30
RU2020142517A (ru) 2021-01-27
TW202222839A (zh) 2022-06-16
ZA201708589B (en) 2018-11-28
PH12017502358A1 (en) 2018-06-25
CR20170600A (es) 2018-02-28
CN114773479A (zh) 2022-07-22
CU20170169A7 (es) 2018-07-05
KR102059059B1 (ko) 2020-02-12
RU2018102798A3 (ru) 2020-05-22
UY36751A (es) 2017-01-31
IL256376A (en) 2018-02-28
IL295859B2 (en) 2025-07-01
EA036395B1 (ru) 2020-11-05
WO2016207858A1 (en) 2016-12-29
EA201890145A1 (ru) 2018-07-31
CN114380914A (zh) 2022-04-22
TWI743039B (zh) 2021-10-21
JP2020114216A (ja) 2020-07-30
MX2022004072A (es) 2022-05-03
CL2017003261A1 (es) 2018-04-20
CA2990764A1 (en) 2016-12-29
US10465011B2 (en) 2019-11-05
IL295859A (en) 2022-10-01
MY185813A (en) 2021-06-10
TW201722993A (zh) 2017-07-01
MX2017017144A (es) 2018-05-28
AU2019264514A1 (en) 2019-12-05
EP3313891A1 (en) 2018-05-02
TWI820482B (zh) 2023-11-01
CN107922505B (zh) 2022-05-06
US20240067750A1 (en) 2024-02-29
HK1250990A1 (zh) 2019-01-18
US20170022292A1 (en) 2017-01-26
RU2018102798A (ru) 2019-07-29
KR20190142448A (ko) 2019-12-26
JP7587550B2 (ja) 2024-11-20
IL256376B (en) 2022-09-01
JOP20160131B1 (ar) 2022-03-14
IL318883A (en) 2025-04-01
BR112017027778A2 (pt) 2018-10-09
ECSP18005520A (es) 2018-04-30
NZ777273A (en) 2025-05-30
PE20180480A1 (es) 2018-03-07
AU2021273615B2 (en) 2024-12-12
JOP20200312A1 (ar) 2017-06-16
US20200115468A1 (en) 2020-04-16
JP2024026169A (ja) 2024-02-28
JP6698711B2 (ja) 2020-05-27
KR20180019733A (ko) 2018-02-26
CU24498B1 (es) 2021-01-12
JP2022116069A (ja) 2022-08-09
MY194928A (en) 2022-12-23
AU2019264514B2 (en) 2021-12-09
US20180355056A1 (en) 2018-12-13
MA42243A (fr) 2018-05-02
AU2021273615A1 (en) 2021-12-16
TN2017000536A1 (en) 2019-04-12
AU2016281957B2 (en) 2019-08-15
MX391310B (es) 2025-03-21
CN107922505A (zh) 2018-04-17
AU2025201731A1 (en) 2025-04-03
JP2018526976A (ja) 2018-09-20
CO2017013356A2 (es) 2018-03-20

Similar Documents

Publication Publication Date Title
IL279606A (en) Anti-TREM2 antibodies and methods of using them
ZA201708589B (en) Factor xi antibodies and methods of use
IL259495A (en) Antibodies and methods for using them
IL257636A (en) Anti-tigit antibodies and methods of use
ZA201706323B (en) Anti-pvrig antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL259681A (en) New antibodies against claudin and methods of using them
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
IL246736B (en) Anti-jagged1 antibodies and methods of use
IL267538A (en) Antibodies against factor xi and methods of their use